RAVIMIAMET

Åslaug Helland
Oslo University Hospital Hf
Taarnbygget, Kirkeveien 166
0450 Oslo
NORWAY

27.09.2024 nr RKU-4/76

DECISION

to grant authorisation for clinical trial on the basis of Regulation (EU) No 536/2014 of the European Parliament and of the council

State Agency of Medicines has received the application from sponsor Oslo University Hospital Hf on 27.08.2024 to conduct a clinical trial under the conditions stipulated in Regulation (EU) No 536/2014 art 5 (1) and § 99^1 (1) of Estonian Medicinal Products Act (MPA).

Based on art 8 of Regulation (EU) No 536/2014, considering the aspects covered by Part I and Part II of the assessment report, on the basis of § 99^6 section 1 p 1 and (3) of Medicinal Product Act

State Agency of Medicines has decided to give the approval to conduct the clinical study protocol no ESR-19-14434 under the following conditions:

protocol no: ESR-19-14434 (Version 9.0, dated November 29, 2022)

full title of the trial: DART (19-14434) Durvalumab (MEDI4736) After chemoRadioTh (DART) for NSCLC patients – a phase II translational and biomarker study investigating PDL1 positive and negative patients

sponsor of the trial: Oslo University Hospital Hf

number of subjects in Estonia: 10

principal investigators and study locations:

- Dr Kersti Oselin, North Estonia Medical Centre Foundation, J. Sütiste tee 19, 13419 Tallinn, Estonia

The addressee may file a challenge with State Agency of Medicines within 30 days as of the day when the addressee became or should have become aware of the decision as prescribed in Code of Administrative Procedure § 71(1). If the addressee wishes to have the decision to annulled by the administrative court, he or she may submit a complaint to the Tartu Administrative Court as prescribed in § 7(1) and § 46(1) of the Code of Administrative Court Procedure within 30 days after the date on which the decision was notified to the applicant.

(digitally signed)

Katrin Kiisk
Director General